A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) clinical trial is enrolling its first patients.
The successful development of new targeted tissue-agnostic cancer drugs will be tied to the use of real-world data and new clinical trial formats.
The companies will work together first to develop a companion diagnostic for Bayer's TRK inhibitor larotrectinib, with opportunities to expand to other drugs and drug candidates thereafter.
The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.